LOGIN  |  REGISTER
Recursion
Cue Biopharma

Nyxoah: Publication Relating To Transparency Notifications

November 18, 2024 | Last Trade: US$5.71 0.37 -6.09

Publication relating to transparency notifications

Mont-Saint-Guibert (Belgium), November 18, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

On November 15, 2024, Nyxoah received a transparency notification from ResMed Inc. following the passive crossing of a threshold. Based on the notification, ResMed Inc. holds 1,727,864 voting rights, representing 4.62% of the total number of voting rights on October 9, 2024 (37,389,015).

The notification dated November 5, 2024 contains the following information:

  • Reason for the notification: passive crossing of a threshold
  • Notification by: a person that notifies alone
  • Persons subject to the notification requirement:
    • ResMed Inc. (with address at 9001 Spectrum Center Boulevard, San Diego, CA 92123, USA)
  • Date on which the threshold was crossed: October 9, 2024
  • Threshold that is crossed: 5%
  • Denominator: 37,389,015
  • Notified details:
A) Voting rightsPrevious notificationAfter the transaction

 
# of voting rights# of voting rights% of voting rights
Holders of voting rights
 
Linked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities
ResMed Inc.1,619,7561,727,864
 

 

 

 
TOTAL1,727,864 04.62%0.00%
  • Full chain of controlled undertakings through which the holding is effectively held: No indirect holding of voting securities. ResMed Inc. is not a controlled entity.

Contact:
Nyxoah
John Landry, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page